Cargando…
Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction
OBJECTIVE: Beyond reducing inflammation and troponin T (TnT) release, the interleukin-6 receptor antagonist tocilizumab reduces neutrophil counts in patients with non-ST segment elevation myocardial infarction (NSTEMI). It is unclear if this is related to formation of neutrophil extracellular traps...
Autores principales: | Helseth, Ragnhild, Kleveland, Ola, Ueland, Thor, Wiseth, Rune, Damas, Jan Kristian, Broch, Kaspar, Michelsen, Annika, Bendz, Bjørn, Gullestad, Lars, Aukrust, Pål, Seljeflot, Ingebjørg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112443/ https://www.ncbi.nlm.nih.gov/pubmed/33972404 http://dx.doi.org/10.1136/openhrt-2020-001492 |
Ejemplares similares
-
Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction
por: Ueland, Thor, et al.
Publicado: (2018) -
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)
por: Anstensrud, Anne Kristine, et al.
Publicado: (2019) -
Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab
por: Woxholt, Sindre, et al.
Publicado: (2023) -
Patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris randomised to an invasive versus conservative strategy: angiographic and procedural results from the After Eighty study
por: Tegn, Nicolai, et al.
Publicado: (2020) -
IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction
por: Orrem, Hilde L., et al.
Publicado: (2018)